temocillin
Small moleculeexperimental
Temocillin is a β-lactamase-resistant penicillin introduced by Beecham, marketed by Eumedica Pharmaceuticals as Negaban. It is used primarily for the treatment of multiple drug-resistant, Gram-negative bacteria. It is actually a 6-methoxy Ticarcillin; it is also a carboxypenicillin. — Wikipedia
Clinical trial activity
9 trials · 13 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
3
Phase 4
5
Earliest trial started Jun 1, 2011 (NCT02285075)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Penicillin-binding protein 1INHIBITOR
pbp1 inhibitor
- Bacterial penicillin-binding proteinINHIBITOR
Bacterial penicillin-binding protein inhibitor
Primarily active against Gram-negatives.
- D-alanyl-D-alanine carboxypeptidase DacB (dacB) ↗
- Peptidoglycan D,D-transpeptidase FtsI (ftsI) ↗
- Penicillin-binding protein 1A (mrcA) ↗
- Penicillin-binding protein 1B (mrcB) ↗
- D-alanyl-D-alanine carboxypeptidase DacA (dacA) ↗
- Peptidoglycan D,D-transpeptidase MrdA (mrdA) ↗
- D-alanyl-D-alanine carboxypeptidase DacC (dacC) ↗
Chemistry & pharmacology
Loading structure…
SMILES
CO[C@@]1(NC(=O)C(C(=O)O)c2ccsc2)C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@@H]21- Mol. weight
- 414.46 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTemocillin ↗
- ChEMBLCHEMBL1276310 ↗
Also known as
- brl 17421
- brl-17421 [as sodium]
- brl-17421 [as sodium]
- disodium 6beta-(2-carboxy-2-thien-3-ylacetamido)-6alpha-methoxypenicillanate
- temocillin
- temocillin
- temocillin
- temocillin
- temocillin
- temocillin
- temocillin
- temocillin, (2s-(2alpha,5alpha,6alpha))-isomer
- temocillin disodium
- temocillin disodium
- temocillin disodium
- temocillin disodium
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05565222 | Phase 3 | Jan 31, 2023 | Assistance Publique - Hôpitaux de Paris |
| NCT04478721 | Phase 3 | Sep 30, 2020 | Fundación Pública Andaluza, Hospital Universitario Virgen Macarena, Spanish Network for Research in Infectious Diseases |
| NCT03543436 | Phase 3 | Jul 31, 2018 | Assistance Publique - Hôpitaux de Paris, Groupe Hospitalier Paris Saint Joseph |
| NCT03557840 | N/A | Jul 15, 2018 | Université catholique de Louvain |
| NCT02260102 | Phase 4 | Oct 1, 2016 | Université catholique de Louvain |
| NCT02959957 | Phase 4 | May 1, 2016 | Government of Sweden, Linkoping University |
| NCT02681263 | Phase 4 | Apr 1, 2016 | French National Network of Clinical Research in Infectious Diseases, University of Grenoble |
| NCT01543347 | Phase 4 | Feb 1, 2012 | Belpharma s.a., University of Birmingham |
| NCT02285075 | Phase 4 | Jun 1, 2011 | AZ Sint-Jan, Université catholique de Louvain |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Université catholique de Louvain | Academic/Hospital | 3 | 2 | 2 | 2011 |
| Assistance Publique - Hôpitaux de Paris | Academic/Hospital | 2 | 2 | 1 | 2018 |
| AZ Sint-Jan | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Belpharma s.a. | For profit | 1 | 1 | 1 | 2012 |
| French National Network of Clinical Research in Infectious Diseases | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Fundación Pública Andaluza | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Government of Sweden | Government | 1 | 1 | 1 | 2016 |
| Groupe Hospitalier Paris Saint Joseph | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Hospital Universitario Virgen Macarena | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Linkoping University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Spanish Network for Research in Infectious Diseases | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Birmingham | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of Grenoble | Academic/Hospital | 1 | 1 | 1 | 2016 |
13 organizations
Page 1 / 1